Clinical outcome analysis of non-small cell lung cancer patients with brain metastasis receiving metastatic brain tumor resection surgery: a multicenter observational study

被引：0

作者：

Hsu, Ping-Chih ^{[1
,2
]}

Chiu, Li-Chung ^{[1
,2
]}

Chen, Ko-Ting ^{[2
,3
]}

Wang, Chun-Chieh ^{[2
,4
]}

Wu, Chen-Te ^{[5
]}

Wu, Chiao-En ^{[2
,6
]}

Ko, Ho-Wen ^{[1
,2
]}

Kuo, Scott Chih-Hsi ^{[1
,2
]}

Lin, Yu-Ching ^{[2
,7
]}

Wang, Chin-Chou ^{[2
,8
]}

Yang, Cheng-Ta ^{[1
,9
,10
]}

机构：

[1] Chang Gung Mem Hosp Linkou, Div Thorac Med, Dept Internal Med, Taoyuan 33305, Taiwan

[2] Chang Gung Univ, Dept Med, Coll Med, Taoyuan 33302, Taiwan

[3] Chang Gung Mem Hosp Linkou, Dept Neurosurg, Taoyuan 33305, Taiwan

[4] Chang Gung Mem Hosp, Div Radiat Oncol, Linkou Branch, Taoyuan 33305, Taiwan

[5] Chang Gung Mem Hosp, Dept Radiol, Linkou Branch, Taoyuan 33305, Taiwan

[6] Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Dept Internal Med, Taoyuan 33305, Taiwan

[7] Chang Gung Mem Hosp, Chiayi Branch, Div Thorac Oncol, Dept Resp & Crit Care Med, Chiayi 613, Chiayi County, Taiwan

[8] Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung 83301, Taiwan

[9] Taoyuan Chang Gung Mem Hosp, Dept Internal Med, Taoyuan 33378, Taiwan

[10] Chang Gung Univ, Coll Med, Dept Resp Therapy, Taoyuan 33302, Taiwan

来源：

AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 08期

关键词：

Non-small cell lung cancer (NSCLC); brain tumor; brain metastasis; neurosurgery; adenocarcinoma; STEREOTACTIC RADIOSURGERY; SURVIVAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Brain metastasis is most common in primary non-small cell lung cancer (NSCLC), and some patients require neurosurgical resection for intracranial disease control. Because advances in systemic therapies for metastatic NSCLC have been developed in the past decade, we aimed to analyze and determine clinical factors associated with the postresection survival of NSCLC patients with brain metastasis who underwent neurosurgery followed by systemic therapy. Between January 2017 and December 2021, data for 93 NSCLC patients with brain metastasis treated with neurosurgery followed by systemic therapy at Linkou, Kaohsiung and Chiayi Chang Gung Memorial Hospitals were retrospectively retrieved for analysis. For all study patients, median postresection survival was 34.36 months (95% confidence interval (CI), 28.97-39.76), median brain metastasis (BM)-free survival was 26.90 months (95% CI, 22.71-31.09), and overall survival (OS) was 41.13 months (95% CI, 34.47-47.52). In multivariate analysis, poor performance status (Eastern Cooperative Oncology Group performance status (ECOG PS) =2) and concurrent liver metastasis were identified as independent unfavorable factors associated with significantly shortened postresection survival (P<0.001). The histological type adenocarcinoma was associated with significantly longer postresection survival (P = 0.001). The median postresection survival for adenocarcinoma and nonadenocarcinoma patients was 36.23 and 10.30 months, respectively (hazard ratio (HR) = 0.122; 95% CI, 0.035-0.418; P<0.001); that for patients with and without concurrent liver metastasis was 11.43 and 36.23 months, respectively (HR = 22.18; 95% CI, 5.827-84.459; P<0.001). Patients with preserved ECOG PS, adenocarcinoma histology type and no concurrent liver metastasis appeared to have better postresection survival than nonadenocarcinoma patients. Our results provide counseling and decision-making references for neurosurgery feasibility in NSCLC patients with brain metastasis.

引用

页码：3607 / 3617

页数：11

共 33 条

[1] The Role of UK Oncogene-Focussed Patient Groups in Supporting and Educating Patients with Oncogene-Driven NSCLC: Results from a Patient-Devised Survey [J].